metoclopramide has been researched along with Lung Neoplasms in 46 studies
Metoclopramide: A dopamine D2 antagonist that is used as an antiemetic.
metoclopramide : A member of the class of benzamides resulting from the formal condensation of 4-amino-5-chloro-2-methoxybenzoic acid with the primary amino group of N,N-diethylethane-1,2-diamine.
Lung Neoplasms: Tumors or cancer of the LUNG.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The clinical efficacy and tolerability of a new nasal spray formulation of metoclopramide (MTC) was evaluated in terms of its ability to prevent the nausea and vomiting induced by a moderately emetic chemotherapy (cisplatin 20 mg/m2 weekly as radioenhancer+radiotherapy for a fractionated total of 60 Gy) in 12 patients with non-small-cell lung cancer, stage IIIB." | 9.07 | Efficacy and tolerability of nasally administered compared to parenterally administered metoclopramide in the symptomatic treatment of chemotherapy-induced emesis in cancer outpatients. A controlled clinical study. ( Confalonieri, M; Dimaiuta, M; Scanni, A; Tomirotti, M, 1994) |
| "The usefulness of alprazolam (minor tranquilizer) used in combination with metoclopramide plus methylprednisolone for the prevention and control of emesis induced by chemotherapies, including 5-day continuous intravenous infusion of cisplatin (25 mg/m2/day) for advanced lung cancer, was evaluated using a double-blind randomized crossover design." | 9.07 | Antiemetic efficacy of alprazolam in the combination of metoclopramide plus methylprednisolone. Double-blind randomized crossover study in patients with cisplatin-induced emesis. ( Mori, K; Saito, Y; Tominaga, K, 1993) |
| "Forty-two patients with advanced lung cancer undergoing chemotherapy containing cisplatin (80 mg/m2) were submitted to a randomized controlled trial to evaluate the effect of the combination of metoclopramide and dexamethasone for the treatment of delayed cisplatin-induced emesis occurring more than 24 hours after cisplatin administration." | 9.06 | Control of cisplatin-induced delayed emesis with metoclopramide and dexamethasone: a randomized controlled trial. ( Eguchi, K; Fujiwara, Y; Fukuda, M; Mae, M; Ohe, Y; Saijo, N; Sasaki, S; Sasaki, Y; Shinkai, T; Tamura, T, 1989) |
| "Forty patients with advanced lung cancer who had received chemotherapy containing cisplatin (80 mg/m2) were accrued for a randomized controlled trial to evaluate the additional effect of prochlorperazine on the combination of high-dose metoclopramide and dexamethasone for the treatment of acute cisplatin-induced emesis." | 9.06 | [A randomized controlled trial of acute and delayed cisplatin-induced emesis with metoclopramide, dexamethasone and prochlorperazine]. ( Eguchi, K; Inoue, I; Nino, S; Saijo, N; Sakurai, M; Sasaki, Y; Shinkai, T; Suemasu, K; Tamura, T; Umehara, H, 1987) |
| "Radiation induced cytotoxicity was potentiated by neutralized metoclopramide (nMCA; Neu-Sensamide, Oxigene Inc) when a human lung adenocarcinoma (H2981) transplanted into scid mice and an adeno-type 12 virus induced mouse sarcoma (A12B3) inoculated into CBA mice were exposed in vivo to low dose radiation at single doses of 1 and 2 Gy respectively." | 7.69 | Neutral metoclopramide induces tumor cytotoxicity and sensitizes ionizing radiation of a human lung adenocarcinoma and virus induced sarcoma in mice. ( Hua, J; Olsson, AR; Pero, RW; Sheng, Y, 1997) |
| "To evaluate the efficacy of a combined therapy of prednisolone and alprazolam for controlling cisplatin-induced delayed emesis, a study involving 14 non-small cell lung cancer patients receiving cisplatin (80 mg/m2) was conducted." | 7.68 | [A combined anti-emesis therapy of oral prednisolone and alprazolam for cisplatin-induced delayed emesis]. ( Horio, Y; Iwahara, T; Minami, H; Sakai, S; Shibagaki, T; Shimokata, K; Watanabe, A, 1990) |
| "Metoclopramide was administered by continuous infusion to two groups each of 14 patients on chemotherapy, randomized to receive either doses adjusted to individual pharmacokinetic parameters or doses adjusted as usual to body weight." | 6.67 | Continuous infusion of high-dose metoclopramide: comparison of pharmacokinetically adjusted and standard doses for the control of cisplatin-induced acute emesis. ( Brechot, JM; Chastang, C; Delattre, C; Dupeyron, JP; Laaban, JP; Rochemaure, J, 1991) |
| "19 mg/l with doses which varied considerably owing to marked scattering of pharmacokinetic parameters." | 6.66 | [Dosage adjustment of metoclopramide for controlling vomiting induced by cisplatin: pharmacokinetic approach]. ( Brechot, JM; Delattre, C; Delfour, C; Dupeyron, JP; Guyon, F; Lebeau, B; Rochemaure, J, 1988) |
| "Crizotinib is an orally active multi-target tyrosine kinase inhibitor which is the standard of care in patients with anaplastic lymphoma kinase translocated non-small-cell lung cancer." | 5.42 | When crizotinib-induced bradycardia becomes symptomatic: role of concomitant drugs. ( Aieta, M; Gallucci, G; Lombardi, L; Tartarone, A, 2015) |
| "and metoclopramide 0." | 5.29 | Treatment of cisplatin-related nausea and vomiting with a combination of ondansetron and metoclopramide: a pilot study. ( Cannata, G; Gebbia, N; Gebbia, V; Testa, A, 1996) |
| "Metoclopramide was administered four times intravenously at a dose of 1." | 5.27 | [Antiemetic combination of metoclopramide and methylprednisolone for cisplatin-induced vomiting]. ( Amano, H; Fujimoto, K; Saito, H; Shimokata, K; Tsunekawa, H; Yasuda, Y; Yoshii, S, 1985) |
| "Intravenous antiemetic combinations containing a 5-HT3 receptor antagonist (like metoclopramide, ondansetron, or granisetron) with dexamethasone have become the standard therapy for the treatment of acute chemotherapy-induced vomiting." | 5.08 | Oral combination antiemetics in patients with small cell lung cancer receiving cisplatin or cyclophosphamide plus doxorubicin. ( Clark, RA; Cleri, LB; Gralla, RJ; Kris, MG; Pisters, KM; Tyson, LB, 1995) |
| "We carried out a randomized, single-blind, cross-over trial to compare the antiemetic effect, for both acute and delayed emesis, of granisetron plus dexamethasone (GRN+Dx) with that of high-dose metoclopramide plus dexamethasone (HDMP+Dx)." | 5.07 | A randomized cross-over study of high-dose metoclopramide plus dexamethasone versus granisetron plus dexamethasone in patients receiving chemotherapy with high-dose cisplatin. ( Arioka, H; Eguchi, K; Karato, A; Kunikane, H; Nakashima, H; Nisio, M; Ohe, Y; Ohmatsu, H; Shinkai, T; Tamura, T, 1994) |
| "The clinical efficacy and tolerability of a new nasal spray formulation of metoclopramide (MTC) was evaluated in terms of its ability to prevent the nausea and vomiting induced by a moderately emetic chemotherapy (cisplatin 20 mg/m2 weekly as radioenhancer+radiotherapy for a fractionated total of 60 Gy) in 12 patients with non-small-cell lung cancer, stage IIIB." | 5.07 | Efficacy and tolerability of nasally administered compared to parenterally administered metoclopramide in the symptomatic treatment of chemotherapy-induced emesis in cancer outpatients. A controlled clinical study. ( Confalonieri, M; Dimaiuta, M; Scanni, A; Tomirotti, M, 1994) |
| "The usefulness of alprazolam (minor tranquilizer) used in combination with metoclopramide plus methylprednisolone for the prevention and control of emesis induced by chemotherapies, including 5-day continuous intravenous infusion of cisplatin (25 mg/m2/day) for advanced lung cancer, was evaluated using a double-blind randomized crossover design." | 5.07 | Antiemetic efficacy of alprazolam in the combination of metoclopramide plus methylprednisolone. Double-blind randomized crossover study in patients with cisplatin-induced emesis. ( Mori, K; Saito, Y; Tominaga, K, 1993) |
| "In order to decide the administration method of metoclopramide for prevention or control of chemotherapy-induced nausea and vomiting in multidrug chemotherapy, with cisplatin 5-day continuous intravenous infusion (25 mg/m2/day) for patients with advanced lung cancer, a randomised crossover study of intermittent bolus infusion (1 mg/kg, 30 min, every 8 h, day 1-5) and continuous infusion (3 mg/kg/24 h, 120 h) of metoclopramide was performed." | 5.07 | Comparison of continuous and intermittent bolus infusions of metoclopramide during 5-day continuous intravenous infusion with cisplatin. ( Miyazawa, N; Mori, K; Saitou, Y; Tominaga, K, 1991) |
| "Forty-two patients with advanced lung cancer undergoing chemotherapy containing cisplatin (80 mg/m2) were submitted to a randomized controlled trial to evaluate the effect of the combination of metoclopramide and dexamethasone for the treatment of delayed cisplatin-induced emesis occurring more than 24 hours after cisplatin administration." | 5.06 | Control of cisplatin-induced delayed emesis with metoclopramide and dexamethasone: a randomized controlled trial. ( Eguchi, K; Fujiwara, Y; Fukuda, M; Mae, M; Ohe, Y; Saijo, N; Sasaki, S; Sasaki, Y; Shinkai, T; Tamura, T, 1989) |
| "Forty patients with advanced lung cancer who had received chemotherapy containing cisplatin (80 mg/m2) were accrued for a randomized controlled trial to evaluate the additional effect of prochlorperazine on the combination of high-dose metoclopramide and dexamethasone for the treatment of acute cisplatin-induced emesis." | 5.06 | [A randomized controlled trial of acute and delayed cisplatin-induced emesis with metoclopramide, dexamethasone and prochlorperazine]. ( Eguchi, K; Inoue, I; Nino, S; Saijo, N; Sakurai, M; Sasaki, Y; Shinkai, T; Suemasu, K; Tamura, T; Umehara, H, 1987) |
| "The present trial was designed to compare the effect of metoclopramide(MCP) + dexamethasone(DM) (Method A) with that of MCP + DM + lorazepam(Lor) (Method B) in the treatment of CDDP (cis-diamminedichloroplatinum)-induced nausea and vomiting in a randomized fashion." | 5.06 | [Anti-emetic treatment with metoclopramide and other drugs during CDDP therapy]. ( Arai, R; Furuse, K; Hayashi, S; Kawahara, M; Kiyota, T; Kodama, N; Tsuruta, S, 1987) |
| "Radiation induced cytotoxicity was potentiated by neutralized metoclopramide (nMCA; Neu-Sensamide, Oxigene Inc) when a human lung adenocarcinoma (H2981) transplanted into scid mice and an adeno-type 12 virus induced mouse sarcoma (A12B3) inoculated into CBA mice were exposed in vivo to low dose radiation at single doses of 1 and 2 Gy respectively." | 3.69 | Neutral metoclopramide induces tumor cytotoxicity and sensitizes ionizing radiation of a human lung adenocarcinoma and virus induced sarcoma in mice. ( Hua, J; Olsson, AR; Pero, RW; Sheng, Y, 1997) |
| "To evaluate the efficacy of a combined therapy of prednisolone and alprazolam for controlling cisplatin-induced delayed emesis, a study involving 14 non-small cell lung cancer patients receiving cisplatin (80 mg/m2) was conducted." | 3.68 | [A combined anti-emesis therapy of oral prednisolone and alprazolam for cisplatin-induced delayed emesis]. ( Horio, Y; Iwahara, T; Minami, H; Sakai, S; Shibagaki, T; Shimokata, K; Watanabe, A, 1990) |
| " The nausea and vomiting were reasonably well controlled with methylprednisolone and metoclopramide." | 3.67 | [Clinical study of chemotherapy (PPM therapy) with cisplatin, peplomycin and mitomycin C in squamous cell lung cancer]. ( Arai, S; Honda, Y; Ito, T; Kato, M; Kawata, Y; Kori, Y; Koyama, M, 1986) |
| "Metoclopramide was administered by continuous infusion to two groups each of 14 patients on chemotherapy, randomized to receive either doses adjusted to individual pharmacokinetic parameters or doses adjusted as usual to body weight." | 2.67 | Continuous infusion of high-dose metoclopramide: comparison of pharmacokinetically adjusted and standard doses for the control of cisplatin-induced acute emesis. ( Brechot, JM; Chastang, C; Delattre, C; Dupeyron, JP; Laaban, JP; Rochemaure, J, 1991) |
| "19 mg/l with doses which varied considerably owing to marked scattering of pharmacokinetic parameters." | 2.66 | [Dosage adjustment of metoclopramide for controlling vomiting induced by cisplatin: pharmacokinetic approach]. ( Brechot, JM; Delattre, C; Delfour, C; Dupeyron, JP; Guyon, F; Lebeau, B; Rochemaure, J, 1988) |
| "Thirty-two patients with primary lung cancer receiving combination chemotherapy including cisplatin at a dosage of 80-120 mg/m2 were entered into an antiemetic randomized crossover trial." | 2.66 | [Antiemetic effects of combinations of metoclopramide, droperidol and dexamethasone for the prevention of cisplatin-induced gastro-intestinal toxicity: a randomized crossover trial]. ( Fujii, M; Kamei, H; Kiura, K; Okabe, K; Toki, H, 1987) |
| " A further trial is necessary to determine the optimal dosage and scheduling of the available agents." | 2.66 | [Randomized crossover trial of the antiemetic effects obtained with metoclopramide and droperidol versus those obtained with metoclopramide, droperidol and methylprednisolone in patients receiving cis-platinum chemotherapy]. ( Fujii, M; Kiura, K; Okabe, K; Tamai, M; Toki, H, 1986) |
| "Diphenhydramine was used because of its possible antiemetic properties and its ability to control acute dystonic reactions." | 2.66 | Improved control of cisplatin-induced emesis with high-dose metoclopramide and with combinations of metoclopramide, dexamethasone, and diphenhydramine. Results of consecutive trials in 255 patients. ( Bosl, GJ; Clark, RA; Gralla, RJ; Groshen, S; Kalman, LA; Kelsen, DP; Kris, MG; Reilly, LK; Tyson, LB, 1985) |
| "Four consecutive trials were undertaken to study lorazepam at each of three dosage levels and diphenhydramine when used in combination with iv metoclopramide and dexamethasone in patients receiving cisplatin at 120 mg/m2." | 2.66 | Consecutive dose-finding trials adding lorazepam to the combination of metoclopramide plus dexamethasone: improved subjective effectiveness over the combination of diphenhydramine plus metoclopramide plus dexamethasone. ( Clark, RA; Fiore, JJ; Gralla, RJ; Groshen, S; Kelsen, DP; Kris, MG; Tyson, LB, 1985) |
| "Biopsy revealed a pulmonary squamous cell carcinoma, which was inoperable." | 1.62 | Gastrointestinal dysmotility in a patient with advanced lung cancer: paraneoplastic or drug-induced? ( Dias, RF; Diniz, MML; Nobre, VA; Santos, BC, 2021) |
| "Crizotinib is an orally active multi-target tyrosine kinase inhibitor which is the standard of care in patients with anaplastic lymphoma kinase translocated non-small-cell lung cancer." | 1.42 | When crizotinib-induced bradycardia becomes symptomatic: role of concomitant drugs. ( Aieta, M; Gallucci, G; Lombardi, L; Tartarone, A, 2015) |
| "and metoclopramide 0." | 1.29 | Treatment of cisplatin-related nausea and vomiting with a combination of ondansetron and metoclopramide: a pilot study. ( Cannata, G; Gebbia, N; Gebbia, V; Testa, A, 1996) |
| "Metoclopramide was administered four times intravenously at a dose of 1." | 1.27 | [Antiemetic combination of metoclopramide and methylprednisolone for cisplatin-induced vomiting]. ( Amano, H; Fujimoto, K; Saito, H; Shimokata, K; Tsunekawa, H; Yasuda, Y; Yoshii, S, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 20 (43.48) | 18.7374 |
| 1990's | 20 (43.48) | 18.2507 |
| 2000's | 2 (4.35) | 29.6817 |
| 2010's | 3 (6.52) | 24.3611 |
| 2020's | 1 (2.17) | 2.80 |
| Authors | Studies |
|---|---|
| Dias, RF | 1 |
| Diniz, MML | 1 |
| Santos, BC | 1 |
| Nobre, VA | 1 |
| Gallucci, G | 1 |
| Tartarone, A | 1 |
| Lombardi, L | 1 |
| Aieta, M | 1 |
| Dale, E | 1 |
| Hårsaker, V | 1 |
| Kristoffersen, DT | 1 |
| Bruland, O | 1 |
| Olsen, DR | 1 |
| Arroyo-Cózar, M | 1 |
| Grau Delgado, J | 1 |
| Gabaldón Conejos, T | 1 |
| Inoue, S | 3 |
| Endo, K | 6 |
| Nakamura, R | 1 |
| Itou, H | 1 |
| Murakami, M | 1 |
| Hua, J | 3 |
| Olsson, A | 3 |
| Sheng, Y | 3 |
| Pero, RW | 4 |
| Motlagh, PB | 1 |
| Henriksson, R | 1 |
| Grankvist, K | 1 |
| Ohmatsu, H | 3 |
| Eguchi, K | 3 |
| Shinkai, T | 3 |
| Tamura, T | 3 |
| Ohe, Y | 2 |
| Nisio, M | 1 |
| Kunikane, H | 1 |
| Arioka, H | 1 |
| Karato, A | 1 |
| Nakashima, H | 1 |
| Tomirotti, M | 1 |
| Dimaiuta, M | 1 |
| Confalonieri, M | 1 |
| Scanni, A | 1 |
| Yoshimura, A | 1 |
| Yamano, Y | 1 |
| Gemma, A | 1 |
| Yoshimori, K | 1 |
| Hayashihara, K | 1 |
| Taniguchi, Y | 1 |
| Uematsu, K | 1 |
| Shibuya, M | 1 |
| Kudoh, S | 1 |
| Niitani, H | 1 |
| Cullen, MH | 1 |
| Mori, K | 2 |
| Saito, Y | 1 |
| Tominaga, K | 2 |
| Möller, C | 1 |
| Kjellén, E | 2 |
| Killander, D | 2 |
| Marmor, M | 1 |
| Cleri, LB | 1 |
| Kris, MG | 3 |
| Tyson, LB | 3 |
| Pisters, KM | 1 |
| Clark, RA | 3 |
| Gralla, RJ | 3 |
| Brun, E | 1 |
| Ewers, SB | 1 |
| Jarlman, O | 1 |
| Knöös, T | 1 |
| Malmström, P | 1 |
| Tennvall, J | 1 |
| Sekine, I | 2 |
| Nishiwaki, Y | 2 |
| Kakinuma, R | 2 |
| Kubota, K | 2 |
| Hojo, F | 2 |
| Matsumoto, T | 2 |
| Yokozaki, M | 2 |
| Kodama, T | 2 |
| Gebbia, V | 1 |
| Testa, A | 1 |
| Cannata, G | 1 |
| Gebbia, N | 1 |
| Olsson, AR | 1 |
| Goto, K | 1 |
| Miyamoto, T | 1 |
| Takafuji, J | 1 |
| Ichimura, H | 1 |
| Suzuki, H | 1 |
| Brechot, JM | 2 |
| Dupeyron, JP | 2 |
| Delattre, C | 2 |
| Chastang, C | 1 |
| Laaban, JP | 1 |
| Rochemaure, J | 2 |
| Saitou, Y | 1 |
| Miyazawa, N | 1 |
| Watanabe, A | 1 |
| Horio, Y | 1 |
| Minami, H | 1 |
| Shibagaki, T | 1 |
| Iwahara, T | 1 |
| Sakai, S | 1 |
| Shimokata, K | 2 |
| Roila, F | 1 |
| Basurto, C | 1 |
| Bracarda, S | 1 |
| Picciafuoco, M | 1 |
| Ballatori, E | 1 |
| Del Favero, A | 1 |
| Tonato, M | 1 |
| Hardy, F | 1 |
| Warrington, PS | 1 |
| MacPherson, JS | 1 |
| Hudson, SA | 1 |
| Jefferson, GC | 1 |
| Smyth, JF | 1 |
| Kori, Y | 1 |
| Koyama, M | 1 |
| Kato, M | 1 |
| Honda, Y | 1 |
| Kawata, Y | 1 |
| Arai, S | 1 |
| Ito, T | 2 |
| Navari, RM | 1 |
| Thatcher, N | 1 |
| Cerny, T | 1 |
| Stout, R | 1 |
| Anderson, H | 1 |
| Barber, PV | 1 |
| Wolstenholme, RJ | 1 |
| Barnes, P | 1 |
| Deiraniya, A | 1 |
| Guyon, F | 1 |
| Delfour, C | 1 |
| Lebeau, B | 1 |
| Saijo, N | 2 |
| Sasaki, Y | 2 |
| Fujiwara, Y | 1 |
| Mae, M | 1 |
| Fukuda, M | 1 |
| Sasaki, S | 1 |
| Umehara, H | 2 |
| Sawamura, N | 1 |
| Takahashi, S | 1 |
| Kusano, H | 1 |
| Yokoyama, S | 1 |
| Suemasu, K | 2 |
| Ibe, Y | 1 |
| Naito, S | 1 |
| Fujieda, K | 1 |
| Okubo, S | 1 |
| Morinari, H | 1 |
| Fujii, M | 3 |
| Kiura, K | 3 |
| Kamei, H | 1 |
| Okabe, K | 2 |
| Toki, H | 2 |
| Aasebø, U | 2 |
| Slørdal, L | 1 |
| Prytz, PS | 1 |
| Aarbakke, J | 1 |
| Nino, S | 1 |
| Inoue, I | 1 |
| Sakurai, M | 1 |
| Tamai, M | 1 |
| Saller, R | 2 |
| Hellenbrecht, D | 2 |
| Kodama, N | 1 |
| Furuse, K | 1 |
| Kawahara, M | 1 |
| Arai, R | 1 |
| Tsuruta, S | 1 |
| Hayashi, S | 1 |
| Kiyota, T | 1 |
| Kelsen, DP | 2 |
| Reilly, LK | 1 |
| Groshen, S | 2 |
| Bosl, GJ | 1 |
| Kalman, LA | 1 |
| Fiore, JJ | 1 |
| Myhr, K | 1 |
| Saito, H | 1 |
| Amano, H | 1 |
| Yasuda, Y | 1 |
| Tsunekawa, H | 1 |
| Fujimoto, K | 1 |
| Yoshii, S | 1 |
1 review available for metoclopramide and Lung Neoplasms
| Article | Year |
|---|---|
Progress in identifying clinical relevance of inhibition, stimulation and measurements of poly ADP-ribosylation.
Topics: Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Clinical Trials, Phase I as Topic; Clinica | 1995 |
28 trials available for metoclopramide and Lung Neoplasms
| Article | Year |
|---|---|
CT density in lung cancer patients after radiotherapy sensitized by metoclopramide. A subgroup analysis of a randomized trial.
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Female; Humans; Lung Neoplasms; Male; Metoclopramid | 2010 |
A randomized cross-over study of high-dose metoclopramide plus dexamethasone versus granisetron plus dexamethasone in patients receiving chemotherapy with high-dose cisplatin.
Topics: Adult; Aged; Cisplatin; Cross-Over Studies; Dexamethasone; Drug Therapy, Combination; Female; Granis | 1994 |
Efficacy and tolerability of nasally administered compared to parenterally administered metoclopramide in the symptomatic treatment of chemotherapy-induced emesis in cancer outpatients. A controlled clinical study.
Topics: Administration, Intranasal; Adult; Aged; Carcinoma, Non-Small-Cell Lung; Cisplatin; Female; Humans; | 1994 |
[An early phase II trial combining cisplatin and carboplatin in advanced non-small cell lung cancer].
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-S | 1993 |
Mitomycin, ifosfamide, and cisplatin in non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Carcinoma, Non-Small-Cell | 1993 |
Antiemetic efficacy of alprazolam in the combination of metoclopramide plus methylprednisolone. Double-blind randomized crossover study in patients with cisplatin-induced emesis.
Topics: Adult; Aged; Alprazolam; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non | 1993 |
Oral combination antiemetics in patients with small cell lung cancer receiving cisplatin or cyclophosphamide plus doxorubicin.
Topics: Administration, Oral; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Sm | 1995 |
A phase I/II evaluation of metoclopramide as a radiosensitiser in patients with inoperable squamous cell carcinoma of the lung.
Topics: Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Female; Humans; Lung Neoplasms; Male; Metoclopram | 1995 |
A randomized cross-over trial of granisetron and dexamethasone versus granisetron alone: the role of dexamethasone on day 1 in the control of cisplatin-induced delayed emesis.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Cisplatin; Cross-Over Studies; Dexamethasone; Drug | 1996 |
Phase II study of high-dose dexamethasone-based association in acute and delayed high-dose cisplatin-induced emesis--JCOG study 9413.
Topics: Antiemetics; Cisplatin; Dexamethasone; Female; Granisetron; Humans; Lung Neoplasms; Male; Metoclopra | 1997 |
[Anti-emetic treatment for patients with non-small cell lung cancer after chemotherapy, usefulness of preventive combination of anti-emetic agents and importance of psychiatric aspect of patients].
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell | 1999 |
[Anti-emetic treatment for patients with lung cancer after chemotherapy, and usefulness of prochlorperazine for psychiatric emesis].
Topics: Aged; Antiemetics; Cisplatin; Drug Administration Schedule; Drug Evaluation; Drug Therapy, Combinati | 2000 |
Continuous infusion of high-dose metoclopramide: comparison of pharmacokinetically adjusted and standard doses for the control of cisplatin-induced acute emesis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Dose-Resp | 1991 |
Comparison of continuous and intermittent bolus infusions of metoclopramide during 5-day continuous intravenous infusion with cisplatin.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small | 1991 |
A pharmacokinetic study of high-dose metoclopramide suppositories.
Topics: Administration, Rectal; Biological Availability; Female; Humans; Lung Neoplasms; Male; Metoclopramid | 1990 |
Comparison of intermittent versus continuous infusion metoclopramide in control of acute nausea induced by cisplatin chemotherapy.
Topics: Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Dexamethasone; Diphenhydramine; Dr | 1989 |
[Dosage adjustment of metoclopramide for controlling vomiting induced by cisplatin: pharmacokinetic approach].
Topics: Adult; Bronchial Neoplasms; Carcinoma, Non-Small-Cell Lung; Cisplatin; Female; Humans; Lung Neoplasm | 1988 |
Control of cisplatin-induced delayed emesis with metoclopramide and dexamethasone: a randomized controlled trial.
Topics: Adult; Aged; Antiemetics; Cisplatin; Dexamethasone; Drug Therapy, Combination; Female; Humans; Infus | 1989 |
[Randomized controlled study of high-dose metoclopramide and dexamethasone in the prevention of CDDP-induced emesis].
Topics: Adult; Aged; Anorexia; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Dexamethasone; Dr | 1986 |
[Antiemetic effects of combinations of metoclopramide, droperidol and dexamethasone for the prevention of cisplatin-induced gastro-intestinal toxicity: a randomized crossover trial].
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as | 1987 |
High-dose metoclopramide and chlorpromazine in the treatment of cisplatin-induced emesis.
Topics: Adult; Aged; Chlorpromazine; Cisplatin; Clinical Trials as Topic; Etoposide; Female; Humans; Kinetic | 1987 |
[A randomized controlled trial of acute and delayed cisplatin-induced emesis with metoclopramide, dexamethasone and prochlorperazine].
Topics: Adult; Aged; Cisplatin; Clinical Trials as Topic; Dexamethasone; Drug Therapy, Combination; Female; | 1987 |
[Randomized crossover trial of the antiemetic effects obtained with metoclopramide and droperidol versus those obtained with metoclopramide, droperidol and methylprednisolone in patients receiving cis-platinum chemotherapy].
Topics: Aged; Cisplatin; Clinical Trials as Topic; Droperidol; Drug Therapy, Combination; Female; Humans; Lu | 1986 |
High doses of metoclopramide or droperidol in the prevention of cisplatin-induced emesis.
Topics: Cisplatin; Clinical Trials as Topic; Droperidol; Head and Neck Neoplasms; Humans; Lung Neoplasms; Ma | 1986 |
[Anti-emetic treatment with metoclopramide and other drugs during CDDP therapy].
Topics: Aged; Cisplatin; Dexamethasone; Female; Humans; Lorazepam; Lung Neoplasms; Male; Metoclopramide; Mid | 1987 |
Improved control of cisplatin-induced emesis with high-dose metoclopramide and with combinations of metoclopramide, dexamethasone, and diphenhydramine. Results of consecutive trials in 255 patients.
Topics: Adult; Aged; Antiemetics; Cisplatin; Clinical Trials as Topic; Dexamethasone; Diphenhydramine; Drug | 1985 |
Consecutive dose-finding trials adding lorazepam to the combination of metoclopramide plus dexamethasone: improved subjective effectiveness over the combination of diphenhydramine plus metoclopramide plus dexamethasone.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anxiety; Cisplatin; Clinical Trials as | 1985 |
Comparison of the antiemetic efficacy of two high-dose benzamides, metoclopramide and alizapride, against cisplatin-induced emesis.
Topics: Adult; Aged; Antiemetics; Cisplatin; Clinical Trials as Topic; Double-Blind Method; Drug Administrat | 1985 |
17 other studies available for metoclopramide and Lung Neoplasms
| Article | Year |
|---|---|
Gastrointestinal dysmotility in a patient with advanced lung cancer: paraneoplastic or drug-induced?
Topics: Aged; Antiemetics; Carcinoma, Squamous Cell; Constipation; Gastrointestinal Agents; Gastrointestinal | 2021 |
When crizotinib-induced bradycardia becomes symptomatic: role of concomitant drugs.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Combined Chemotherapy Protocols; Bradycardia; | 2015 |
Hiccups induced by midazolam during sedation in flexible bronchoscopy.
Topics: Adenocarcinoma; Bronchoscopy; Conscious Sedation; Female; Flumazenil; GABA Modulators; Hiccup; Human | 2012 |
[Relationship between neurotransmitter blood noradrenalin and nausea/emesis after chemotherapy for lung cancer].
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Catecholamines; Cisplatin; Docetaxel; D | 2006 |
[Gastrointestinal disturbance by cancer chemotherapy--recent progress in antiemetic regimens].
Topics: Adult; Aged; Animals; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Domper | 1984 |
Acidic and neutralized metoclopramide formulations sensitize ionizing radiation induced cytotoxicity in a human lung adenocarcinoma xenografted to scid mice.
Topics: Adenocarcinoma; Animals; Female; Humans; Lung Neoplasms; Male; Metoclopramide; Mice; Mice, SCID; Neo | 1995 |
Metoclopramide inhibits the cytotoxicity of cisplatin and enhances the cytotoxicity of epirubicin.
Topics: Animals; Cell Line; Cell Survival; Cells, Cultured; Cisplatin; Cricetinae; Drug Synergism; Epirubici | 1995 |
Treatment of cisplatin-related nausea and vomiting with a combination of ondansetron and metoclopramide: a pilot study.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Cisplatin; Cyclophosphamide; Epirubicin; Female; Hu | 1996 |
Neutral metoclopramide induces tumor cytotoxicity and sensitizes ionizing radiation of a human lung adenocarcinoma and virus induced sarcoma in mice.
Topics: Adenocarcinoma; Animals; Apoptosis; Dose-Response Relationship, Radiation; Female; Humans; Lung Neop | 1997 |
[A combined anti-emesis therapy of oral prednisolone and alprazolam for cisplatin-induced delayed emesis].
Topics: Administration, Oral; Adult; Aged; Alprazolam; Antineoplastic Combined Chemotherapy Protocols; Carci | 1990 |
A pilot study of metoclopramide, dexamethasone, diphenhydramine and lorazepam in prevention of nausea and vomiting in cisplatin-treated male patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dexamethasone; Diphenhydramine; Drug Eval | 1990 |
[Clinical study of chemotherapy (PPM therapy) with cisplatin, peplomycin and mitomycin C in squamous cell lung cancer].
Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcin | 1986 |
Ifosfamide, etoposide, and thoracic irradiation therapy in 163 patients with unresectable small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Combined Modalit | 1987 |
[Antiemetic treatment with metoclopramide and high-dose lorazepam and additional long-term treatment with lorazepam during CDDP administration].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Humans; Lorazepam; Lung Neoplasms | 1988 |
[A case of asthma attack induced by high-dose metoclopramide].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Asthma; Carcinoma, Bronchogenic; Cisplatin; F | 1986 |
[Cisplatin drug therapy. Antiemetic treatment. Experiences with the use of high-dose metoclopramide combined with chlopromazine and prochlorperazine].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chlorpromazine; Cisplatin; Dose-Response Relat | 1985 |
[Antiemetic combination of metoclopramide and methylprednisolone for cisplatin-induced vomiting].
Topics: Aged; Cisplatin; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Lung Neopl | 1985 |